DiscGenics

A clinical stage company developing regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine.

[BioUtah @BioUtah]

Congrats to @DiscGenics for announcing the FDA has allowed Phase III clinical evaluation of their allogeneic, injectable disc progenitor cell therapy for painful lumbar #degenerativediscdisease to proceed. Link below for details. #UtahLifeSciences

https://t.co/y9tBOkLaGI

[DiscGenics @DiscGenics]

We are excited to announce that the U.S. FDA has allowed Phase III clinical evaluation of our allogeneic, injectable disc progenitor #celltherapy (IDCT) for painful lumbar #degenerativediscdisease to proceed. Subject enrollment expected to begin Q4 2024. https://t.co/d4qio9qXNe

[DiscGenics @DiscGenics]

DiscGenics Chairman & CEO @flagg_flanagan to present at #CanaccordGenuity 2024 Musculoskeletal Conference https://t.co/ZNL4HfYAsS #aaos2024

[DiscGenics @DiscGenics]

We are proud to announce that we have partnered with the U.S. Department of Veterans Affairs (VA) to explore the synergy of our Discogenic Cells with the VA's advanced disc-like angle ply structure. Pushing boundaries in spinal health!
https://t.co/7bxOJGTc5H

[DiscGenics @DiscGenics]

We're thrilled to announce that our CEO, @flagg_flanagan, will be presenting at the East-West BioPharma Summit from Oct 2-4 and the 2023 Cell & Gene Meeting on the Mesa from Oct 10-12. Learn more about the event in our press release!
https://t.co/TXAYGz0lCt

[DiscGenics @DiscGenics]

Thrilled to share highlights from our recent podcast with Merge Medical! Dive into the innovative world of DiscGenics and discover the transformative potential of IDCT. A must-listen for those passionate about the future of spinal health!
#IDCT #RegenerativeMedicine #SpinalHealth

[DiscGenics @DiscGenics]

FDA grants Regenerative Medicine Advanced Therapy (#RMAT) designation to IDCT because of its potential to address the unmet medical needs of millions of patients with painful #degenerativediscdisease! https://t.co/DdPSJkr0iV

[DiscGenics @DiscGenics]

Clinical Trial Results: Discogenic progenitor #celltherapy (IDCT) safely increased disc volume & provided rapid, durable improvements in low back pain, function, quality of life & pain med use out to 2 years in patients with #degenerativediscdisease. https://t.co/4OCztoloOn

[DiscGenics @DiscGenics]

Our CEO & Chairman @FlanaganFlagg will present an update on our recently completed US clinical study evaluating IDCT for #degenerativediscdisease at the 41st Annual J.P. Morgan Healthcare Conference on Wed., Jan 11, 2023 at 3:30PM. #JPM23 #JPM2023 https://t.co/PAAjYTTPxC

[DiscGenics @DiscGenics]

Matthew F. Gornet, MD will present 2-year clinical data from #DiscGenics study of injectable discogenic progenitor #celltherapy for #degenerativediscdisease at the @NASSspine annual meeting in Chicago tomorrow! https://t.co/625iMKEthS #NASS22 #NASS2022

[DiscGenics @DiscGenics]

If you’re attending the @alliancerm #CGMesa22, don’t miss CEO Flagg Flanagan’s on-demand update on #DiscGenics first-in-human clinical study of its allogeneic discogenic progenitor #celltherapy for #degenerativediscdisease.

https://t.co/kaeGWIWXBR

[DiscGenics @DiscGenics]

#DiscGenics Senior Process Engineer is in Dublin this week presenting at the Global Bioprocessing, Bioanalytics & ATMP Manufacturing Congress (@lifesciences_GE) on container closure integrity testing for #celltherapy. https://t.co/jamWpZ6GbT

[DiscGenics @DiscGenics]

Positive interim clin data for allogeneic #celltherapy for #degenerativediscdisease presented at #SpineSummit2022. High dose IDCT well tolerated, resulted in statistically significant, clinically meaningful improvements in pain, function & quality of life https://t.co/YeqF33uM2O

[DiscGenics @DiscGenics]

Our CEO & Chairman Flagg Flanagan will present an update on our US and Japanese clinical programs evaluating IDCT for #degenerativediscdisease at the 40th Annual J.P. Morgan Healthcare Conference on Tues., Jan 11, 2022 at 9:00AM EST. #JPM22 #JPM2022 https://t.co/gZGKFRCZcp

[DiscGenics @DiscGenics]

Congratulations to our Chairman & CEO Flagg Flanagan who was recognized by @GoldmanSachs for #entrepreneurship at 2021 Builders + Innovators Summit. #GSInnovator https://t.co/T091wvhOGL

[Nexcelom @Nexcelom]

Scientists @DiscGenics are developing an allogeneic #celltherapy for the treatment of lumbar disc degeneration comprised of discogenic cells, that are grown in a sphere configuration.

#stemcell #academictwitter #phdlife #cellculture

Read more: https://t.co/jGswrhLCCT

[DiscGenics @DiscGenics]

We are pleased to announce our participation in #CGMesa21 this week. Our Chairman & CEO Flagg Flanagan will give an update on the company’s U.S. and Japanese clinical programs evaluating IDCT for #degenerativediscdisease TODAY at 3:15PM PT. Learn more https://t.co/YjAk2IWTnJ

[Spine Review @BeckersSpine]

DiscGenics caps enrollment in lumbar disc degeneration study https://t.co/6zHyTW574B

[BiotechTechNow @MedTechNow_]

Clinical Launches & Updates

~@DiscGenics completes patient enrollment in Japanese #ClinicalStudy 

~@HoyaCanada shares results of spectacle lens follow-up study

~@biotechne commercial release of novel DNAscope™

[DiscGenics @DiscGenics]

Very excited to announce we have completed enrollment in our Japanese clinical study of our #celltherapy for #discdegeneration. Meanwhile in the U.S., all currently enrolled trial subjects have completed their one-year study visits. https://t.co/ZcO3HKnxgZ